文献速递艾滋病与性传播感染结核与非结核分枝杆菌

多替拉韦联合抗逆转录病毒治疗结核与HIV共感染患者:多中心非比较开放标签随机试验

Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial.
PubMed 文献 · Clin Infect Dis · 2020-01-01

本研究为国际多中心、非比较、活性对照、随机开放标签试验,纳入未接受过抗逆转录病毒治疗且CD4+≥50 cells/mm3的HIV-1感染成人,在接受利福平为基础抗结核治疗≤8周时按3:2随机接受多替拉韦(DTG)或依非韦伦(EFV)联合两种核苷类逆转录酶抑制剂治疗52周。主要终点为第48周DTG组血浆HIV-1-RNA<50 copies/mL的受试者比例,结果显示DTG组为75%(52/69,95%CI 65-86%),EFV组为82%(36/44,95%CI 70-93%),DTG组无治疗相关停药导致的失败,结核治疗成功率高,结核相关IRIS不常见(每组4例),结论认为每日两次DTG在利福平治疗期间有效且耐受良好。

要点

  • 利福平治疗期间每日两次DTG联合两种NRTI,第48周病毒学抑制率为75%。
  • DTG组无因毒性停药,无死亡或研究药物更换,结核相关IRIS每组4例。
  • DTG组3例方案定义病毒学失败中2例无获得性耐药,EFV组1例出现NRTI和NNRTI耐药。

核心结论

  • 在接受利福平为基础抗结核治疗的HIV-1感染成人中,每日两次DTG联合两种NRTI有效且耐受良好。

研究设计与样本

  • 国际多中心、非比较、活性对照、随机开放标签研究(INSPIRING,NCT02178592)。
  • 纳入HIV-1感染、未接受过抗逆转录病毒治疗、CD4+≥50 cells/mm3且接受利福平为基础抗结核治疗≤8周的成人,按3:2随机接受DTG(n=69)或EFV(n=44)联合两种NRTI治疗52周。
  • 主要终点为第48周DTG组血浆HIV-1-RNA<50 copies/mL的受试者比例(FDA Snapshot算法,意向治疗暴露人群),研究未设效力比较。

主要发现

  • DTG组基线HIV-1 RNA>100 000 copies/mL者占64%,中位CD4+计数208 cells/mm3;EFV组分别为55%和202 cells/mm3。
  • 第48周应答率DTG组为75%(52/69,95%CI 65-86%),EFV组为82%(36/44,95%CI 70-93%)。
  • DTG组无应答主要由非治疗相关停药驱动(10例失访),无死亡或研究药物更换,EFV组有2例因毒性停药。
  • 方案定义病毒学失败共3例(DTG组2例,无获得性耐药;EFV组1例,出现NRTI和NNRTI耐药)。
  • 结核治疗成功率高,结核相关IRIS不常见(每组4例),无因IRIS停药。

关键数值与推荐

  • DTG用法:结核治疗期间及结核治疗结束后2周内50 mg每日两次,之后50 mg每日一次。
  • EFV用法:600 mg每日一次,联合两种NRTI。
  • 主要终点界值:第48周血浆HIV-1-RNA<50 copies/mL。

临床怎么用

  • 对于接受利福平为基础抗结核治疗的HIV-1感染初治成人(CD4+≥50 cells/mm3),可考虑每日两次DTG联合两种NRTI方案。
  • 治疗期间需关注失访导致的病毒学应答评估偏倚,并监测病毒学失败及耐药发生。
  • 结核相关IRIS不常见,但仍需临床警惕,本研究中无因IRIS停药。

局限性

  • 研究为非比较设计,未设效力比较,不能直接推断DTG与EFV的优劣。
  • 样本量较小(DTG组69例,EFV组44例),结论需更大样本验证。
  • DTG组无应答主要由失访驱动(10例),可能影响应答率解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The concurrent treatment of tuberculosis and human immunodeficiency virus (HIV) is challenging, owing to drug interactions, overlapping toxicities, and immune reconstitution inflammatory syndrome (IRIS). The efficacy and safety of dolutegravir (DTG) were assessed in adults with HIV and drug-susceptible tuberculosis. METHODS: International Study of Patients with HIV on Rifampicin ING is a noncomparative, active-control, randomized, open-label study in HIV-1-infected antiretroviral therapy-naive adults (CD4+ ≥50 cells/mm3). Participants on rifampicin-based tuberculosis treatment ≤8 weeks were randomized (3:2) to receive DTG (50 mg twice daily both during and 2 weeks after tuberculosis therapy, then 50 mg once daily) or efavirenz (EFV; 600 mg daily) with 2 nucleoside reverse transcriptase inhibitors for 52 weeks. The primary endpoint was the proportion of DTG-arm participants with plasma HIV-1-RNA <50 copies/mL (responders) by the Food and Drug Administration Snapshot algorithm (intent-to-treat exposed population) at Week 48. The study was not powered to compare arms. RESULTS: For DTG (n = 69), the baseline HIV-1 RNA was >100 000 copies/mL in 64% of participants, with a median CD4+ count of 208 cells/mm3; for EFV (n = 44), 55% of participants had HIV-1 RNA >100 000 copies/mL, with a median CD4+ count of 202 cells/mm3. The Week 48 response rates were 75% (52/69, 95% confidence interval [CI] 65-86%) for DTG and 82% (36/44, 95% CI 70-93%) for EFV. The DTG nonresponses were driven by non-treatment related discontinuations (n = 10 lost to follow-up). There were no deaths or study drug switches. There were 2 discontinuations for toxicity (EFV). There were 3 protocol-defined virological failures (2 DTG, no acquired resistance; 1 EFV, emergent resistance to nucleoside reverse transcriptase inhibitors and nonnucleoside reverse transcriptase inhibitors). The tuberculosis treatment success rate was high. Tuberculosis-associated IRIS was uncommon (4/arm), with no discontinuations for IRIS. CONCLUSIONS: Among adults with HIV receiving rifampicin-based tuberculosis treatment, twice-daily DTG was effective and well tolerated. CLINICAL TRIALS REGISTRATION: NCT02178592.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Dooley KE, Kaplan R, Mwelase N, et al. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. Clin Infect Dis. 2020. PMID: 30918967. doi:10.1093/cid/ciz256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。